Taking the brake off the immune system: Hypotheses, trials, tribulations, and the evolving discipline of clinical immunopharmacology

Immuno-oncology therapies: a looming mid-life crisis?

“…Initially, the costs of these drugs caused anxiety among payers as they balance affordability and timely access to these drugs [3]. For example, for pembrolizumab the mean duration of treatment in the pivotal melanoma trial was 151 days [4].…”